NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis $4.45 -0.20 (-4.30%) Closing price 04:00 PM EasternExtended Trading$4.52 +0.07 (+1.57%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Verrica Pharmaceuticals Stock (NASDAQ:VRCA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VRCA alerts:Sign Up Key Stats Today's Range$4.45▼$4.7450-Day Range$4.53▼$6.2652-Week Range$3.28▼$9.82Volume113,179 shsAverage Volume93,563 shsMarket Capitalization$76.45 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingHold Company Overview Verrica Pharmaceuticals Inc. is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases. The company’s work centers on topical therapies designed to address conditions for which patients and healthcare providers have limited treatment options. Verrica’s lead product, YCANTHE (cantharidin) topical solution, 0.7%, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children ages 2 and older. The product is administered by a healthcare provider and is intended to treat the contagious viral skin condition through a topical application. The company was founded in 2013 and is based in West Chester, Pennsylvania. In addition to YCANTHE, Verrica is evaluating additional topical drug candidates for dermatological conditions, including certain wart-related indications. Its commercial and development activities are primarily focused on the U.S. dermatology market.AI Generated. May Contain Errors. Read More Verrica Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreVRCA MarketRank™: Verrica Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 31st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVerrica Pharmaceuticals has a consensus price target of $12.67, representing about 180.2% upside from its current price of $4.52.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($2.25) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Verrica Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.75% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 1.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently decreased by 17.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.8 / 5News SentimentN/A News SentimentVerrica Pharmaceuticals has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for VRCA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership4.8 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Verrica Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $55,160.00 in company stock, which represents 0.0710% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,160.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.90% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRCA Stock News HeadlinesVerrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology ConferencesSeptember 10, 2026 | globenewswire.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | globenewswire.comWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.September 18 at 1:00 AM | Stansberry Research (Ad)Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...August 27, 2026 | finance.yahoo.comVerrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027August 27, 2026 | globenewswire.comVerrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 SharesAugust 19, 2026 | insidertrades.comVerrica (VRCA) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | finance.yahoo.comVerrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comSee More Headlines VRCA Stock Analysis - Frequently Asked Questions How have VRCA shares performed this year? Verrica Pharmaceuticals' stock was trading at $8.31 at the beginning of the year. Since then, VRCA stock has decreased by 45.6% and is now trading at $4.52. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.18. The company earned $5.02 million during the quarter, compared to the consensus estimate of $4.51 million. Verrica Pharmaceuticals had a negative net margin of 102.84% and a negative trailing twelve-month return on equity of 407.11%. Read the conference call transcript. When did Verrica Pharmaceuticals' stock split? Verrica Pharmaceuticals's stock reverse split on the morning of Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Centrus Energy (LEU) and Clean Energy Fuels (CLNE). Company Calendar Last Earnings5/12/2026Today9/18/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, VRCA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VRCA CIK1660334 Webwww.verrica.com Phone(484) 453-3300FaxN/AEmployees76Year Founded2013Price Target and Rating Average Price Target for Verrica Pharmaceuticals$12.67 High Price Target$17.00 Low Price Target$9.00 Potential Upside/Downside+184.6%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.89 million Net Margins-102.84% Pretax Margin-102.84% Return on Equity-407.11% Return on Assets-70.17% Debt Debt-to-Equity Ratio0.18 Current Ratio1.45 Quick Ratio1.33 Sales & Book Value Annual Sales$30.32 million Price / Sales2.52 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book2.87Miscellaneous Outstanding Shares17,179,000Free Float8,091,000Market Cap$76.45 million OptionableNo Data Beta1.49 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:VRCA) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
